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Abstract. Background: Neuroblastoma is the third most
common solid tumor in children. Treatment continues to be
challenging. The pathogenesis of neuroblastoma has been
related to expression of the type 1 insulin-like growth factor
receptor (IGF1R) and to transcription factor MYC-N
amplification. Previous studies have shown that MYC-N
expression is disrupted by blockade of the IGF1R with a
specific monoclonal antibody, αIR3. Inhibition of IGF1R
signaling can be accomplished by other agents, including
rapamycin or temsirolimus, which target mTOR (mammalian
target of rapamycin). Materials and Methods: BE-2(c) and
IMR–32 neuroblastoma cell lines were treated with varying
concentrations of αIR3, rapamycin and temsirolimus alone
or in combination and the viable cells were counted. Results:
Blockade of IGF1R signaling significantly inhibited cell
growth as compared to untreated controls (p<0.05), and a
combination of agents was more effective than each agent
alone. Conclusion: The combination of rapamycin or
temsirolimus with αIR3 blocks the IGF1R signaling pathway
and has an antiproliferative effect on neuroblastoma cells
warranting further investigations using inhibitors of IGF1R
signaling as novel combination therapy for neuroblastoma.
Neuroblastoma is the most common extra-cranial solid
tumor of childhood. For the 70% of patients who present
with metastatic disease, prognosis remains poor with an
overall survival of under 40% (1). MYC-N, a transcription
factor found in neuroblastoma that portends a poor
prognosis, is often amplified in these children. A better
understanding of neuroblastoma growth may lead to better
treatment approaches.
Epidemiological studies suggesting a correlation between
high birth weight and the occurrence of neuroblastoma (2)
support the hypothesis that a factor(s) capable of augmenting
somatic growth plays a role in the pathogenesis of this tumor
(3, 4). Insulin-like growth factor I (IGF-I), a peptide growth
factor of the insulin family, is known to stimulate
proliferation, cell survival, and motility in a wide range of
normal and malignant cell types (5). The pathogenesis of
neuroblastoma has been related to the expression of the type
1 insulin-like growth factor receptor (IGF1R), the receptor
that primarily mediates IGF-I actions and IGF1R signaling
can induce MYC-N expression (4).
The IGF1R is a membrane tyrosine kinase receptor which
transduces signals through both the ras/MAPK pathway
(proliferative growth) and the phospho-inositol (PI)-3
kinase/Akt signaling cascade (anti-apoptosis) (6). Binding
of IGFs to the IGF1R is modulated through the actions of
IGF binding proteins (IGFBP) 1 through 6 (6). The IGF1R
can be blocked by a specific monoclonal antibody, αIR3,
which in turn can disrupt MYC-N expression (4). Inhibition
of a portion of the IGF1R signaling pathway can also be
accomplished by other therapies, including rapamycin that
targets mTOR (mammalian target of rapamycin), a
downstream element in the PI3 kinase/Akt pathway.
Rapamycin, which is approved for use in children, is a
macrolide fungicide and a member of the PI3-kinase related
kinase family. It has in vitro cytostatic activity (7) against a
broad range of malignancies occurring in children and
adolescents, including rhabdomyosarcoma, glioblastoma, T-
cell acute lymphoblastic leukemia (8) and osteosarcoma (9).
Rapamycin acts primarily by binding the 12 kd FK506
binding protein (FKBP12) (10) which in turn directly binds
and inhibits mTOR. Subsequently there is a decrease in
cyclin-dependent kinase (cdk) inhibitor turnover, inhibition
of retinoblastoma protein (Rb) phosphorylation, and
increased cyclin D1 turnover, ultimately resulting in cell
cycle arrest at the intersection of the G1 and S phases (11).
Analogues of rapamycin with improved pharmacological
characteristics have been developed including temsirolimus a
rapamycin prodrug available in both intravenous and oral
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formulations. In Phase II clinical trials, temsirolimus has been
given on a weekly schedule to adult patients with metastatic
endometrial cancer, recurrent glioblastoma and advanced breast
cancer or renal cell carcinoma (12). Adverse effects have
included fatigue, rash, mucositis, anorexia, nausea, diarrhea,
thrombocytopenia, leucopenia, anemia and metabolic effects
that have been managed by dose reduction (12). Temsirolimus
was approved by the Food and Drug Administration (FDA) in
May, 2007, for the treatment of advanced renal cell carcinoma
(13). Rapamycin is currently used therapeutically in children,
and dosing data and side effect profiles are established. There
are no current reports of the use of temsirolimus in children.
Inhibition of IGF1R signaling at the IGF1R and at the
downstream element mTOR might be expected to result in
additive or synergistic anti-proliferative effects on human
neuroblastoma. The findings on the effects of inhibition of
IGF1R and mTOR signaling on proliferation in two
neuroblastoma-derived cell lines are reported. The
concentrations of rapamycin that were chosen corresponded
to serum levels achievable with doses approved for use in
children after renal transplantation and are well tolerated
without major side-effects (14).
Materials and Methods
Cells and reagents. The cryopreserved mycoplasma-negative cell
lines IMR–32 and BE–2(c) were purchased from the Lineberger
Comprehensive Cancer Center Tissue Culture Facility (University
of North Carolina, Chapel Hill, NC, USA). Both cell lines were
derived from human neuroblastoma tissue and are maintained by the
American Type Culture Collection (ATCC). The BE–2(c) line
contains 123 copies of the MYC-N gene (15), and the IMR–32 cell
line contains 25 copies of the MYC-N gene (16).
Rapamycin and temsirolimus were purchased from Wyeth
Pharmaceuticals (Madison, NJ, USA). The monoclonal antibody, αIR3,
was a gift from Dr. Judson J. Van Wyk, University of North Carolina at
Chapel Hill, North Carolina, USA. Dilutions of stock were prepared in
sterile PBS prior to all experiments. Alpha-MEM, fetal calf serum, and
penicillin/streptomycin (Invitrogen Corporation, Carlsbad, CA, USA)
were purchased from the UNC Lineberger Comprehensive Cancer
Center Tissue Culture Facility, University of North Carolina.
RNA preparation. The total RNA was prepared from log phase
IMR–32 and BE–2(c) cell cultures using Trizol reagent (Invitrogen
Corporation) a modification of the single step method by
Chomczynski and Sacchi (17). The RNA was stored frozen at
–80˚C until used.
Oligodeoxynucleotides. Oligodeoxynucleotides (oligos) were
purchased from the Lineberger Comprehensive Cancer Center
Nucleic Acids Core Facility (University of North Carolina). The
oligos used in semi-quantitative reverse transcription-PCR (RT-PCR)
of the IGF system are shown in Table I. An 18S ribosomal RNA
primer set purchased from Ambion Incorporated (Austin, TX, USA)
was used as a normative positive control in the semi-quantitative RT-
PCR analyses. All the oligos were designed to span exons so that any
contaminating genomic DNA in the RT-PCR would be
distinguishable from the product derived from RNA by its large size.
Reverse transcription-polymerase chain reaction (RT-PCR). The
reverse transcription of RNA prepared from the IMR–32 and
BE–2(c) cell cultures was performed at 37˚C for 1 hour, as
described by Frohman et al. (18). Following first strand synthesis,
1 μl of the reverse transcription reaction product was amplified by
PCR using the oligo pairs for the IGF system, the 18S control or a
reaction with no input cDNA to serve as a negative control. The
PCR products were run in Tris-borate EDTA (TBE) agarose gels,
stained with ethidium bromide, and visualized under UV light and
photographed using a Polaroid PhotoMaxPro digital camera (Best
Buy, Durham, NC, USA).
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Table I. PCR primers used in RT-PCR analyses to identify expression of human IGF system RNAs.
Gene GenBank accession # Primers Product size
IGF-I NM_000618 5’-GCTTTTGTGATTTCTTGAAGGTGAA-3’ (nt 210 - nt 234 in exon 1)
5’-TCCCTCTACTTGCGTTCTTCAAAT-3’ (nt 599 - nt 576 in exon 4) 389 bp
IGF-II NM_000612 5’ GTGCTTCTCACCTTCTTGGCCTTC 3’ (nt 783 - nt 806 in exon 2)
5’ CCTCAACGCCTCGAGCTCCTT 3’ (nt 1202 - nt 1182 in exon 4) 419 bp
IGF1R NM_000875 5’ GCTGACCTCTGTTACCTCTCCACT3’ (nt 489 - nt 512 in exon2)
5’ GCAAGGACCTTCACAAGGGAT3’ (nt 1034 - nt 1014 in exon 3) 545 bp
IGFBP-1 NM_000596 5’ GTGCAGGAGTCTGACGCCTCCGCT 3’ (nt 606 - nt 629 in exon 1)
5’ GGTGACATGGAGAGCCTTCGA 3’ (nt 794 - nt 774 in exon 2) 188 bp
IGFBP-2 NM_000597 5’ GAGAAGCGCCGGGACGCCGAGTAT 3’ (nt 523 - nt 546 in exon 1)
5’ GGGGGTGGTCGCAGCTTCTT 3’ (nt 794 - nt 775 in exon 2) 271 bp
IGFBP-3 NM_000598 5’ GTCAACGCTAGTGCCGTCAGCCGC 3’ (nt 475 - nt 498 in exon 1)
5’ ATATTCTGTCTCCCGCTTGGA 3’ (nt 762 - nt 742 in exon 2) 287 bp
IGFBP-4 NM_001552 5’ GAGCTGGCGGAGATCGAGGCCATC 3’ (nt 616 - nt 639 in exon 1)
5’ CGCCCCATTGACCTTCATCTT 3’ (nt 795 - nt 775 in exon 2) 179 bp
IGFBP-5 NM_000599 5’ GAGAAGATGGTGTTGCTCA3’ (nt 768 - nt 786 in exon 1)
5’ GCTCACGGGAGTCTCTCTCGA 3’ (nt 1130 - nt 1110 in exon 2) 332 bp
IGFBP-6 NM_002178 5’CTCAGTGCTGCAGCAACTCCAG 3’ (nt 569 - nt 571 in exon 3)
5’ CAGCGACCCCAAGCAGAGCTTTATTG 3’ (nt 966 - nt 941 in exon 4) 397 bp
Anti-proliferative assays. The cells were grown at 37˚C, 5% CO2
in Alpha MEM supplemented with 10% fetal bovine serum, 2 mM
glutamine, and penicillin/streptomycin (control medium, CM). The
cells were seeded in 96 well plates (Costar, Corning, NY, USA) at
1×104/ml or 1×105/ml, and untreated triplicate specimens for each
experimental group were serum starved for twenty-four hours prior
to treatment, and then allowed to grow for 48 hours in one of the
following media: CM (experimental control), CM plus 0.5 μg/ml
monoclonal antibody directed against human myoglobin (IgG) was
included in all the αIR3 blocking experiments to serve as an
isotypic control antibody, CM plus 0.5 μg/ml αIR3 (19), CM plus 1,
10 or 100 ng/ml rapamycin, CM plus 1, 10 or 100 ng/ml
temsirolimus, CM plus rapamycin and αIR3 (1 ng/ml and 0.5
μg/ml, respectively) and CM plus temsirolimus and αIR3 (10 ng/ml
and 0.5 μg/ml, respectively). The viable cells were counted in
triplicate every 24 hours using trypan blue exclusion.
Propidium iodide (PI) assay. The cells were plated in triplicate in 96
well plates (Costar) at a density of 1×104/well and incubated for 24
hours with 0.3 μg/ml PI (20) and CM plus 0.5 μg/ml IgG, CM plus
0.5 μg/ml αIR3, CM plus rapamycin (1 ng/ml), CM plus
temsirolimus (10 ng/ml), CM plus rapamycin and αIR3 (1 ng/ml and
0.5 μg/ml, respectively) or CM plus temsirolimus and αIR3 (10 ng/ml
and 0.5 μg/ml, respectively). The cells were examined using
fluorescent microscopy and light microscopy at one and 24 hours.
Propidium iodide is a fluorescent phenanthridine dye that intercalates
into DNA (20) and is impermeable to living cells. All the fluorescent
(dead) and non-fluorescent (live) cells were counted at each time-
point, and the percentage of dead cells was calculated.
Statistical analyses. Statistical analyses including one-way ANOVA
and Student’s t-test, were performed using the Sigma Stat program,
version 1 (Jandel Scientific, San Rafael, CA, USA).
Results
Expression of the IGF system components in BE-2(c) and
IMR-32 cells. The RT-PCR analyses revealed that both the
cell lines expressed RNAs encoding IGF1R and IGF-II, as
well as IGFBPs 2 through 6 (Figure 1). Each replicon was
the predicted size as indicated in Table I. Neither IGF-I nor
IGFBP-1 transcripts were detected. IGF-II was more
abundantly expressed in the BE–2(c) cells than in the
IMR–32 cells.
Effect of inhibition of mTOR on neuroblastoma cell number.
Dose response curves were completed for both rapamycin
(Figures 2A and 3A) and temsirolimus (Figure 2B and 3B)
in both the cell lines. When serum-starved BE–2(c) cells
were incubated with rapamycin for 24 or 48 hours cell
number did not increase over time compared to the untreated
control cultures (Figure 2A). In fact, the higher
concentrations of rapamycin (10 ng/ml and 100 ng/ml)
caused the cell number to decrease below the levels at time
zero. Similar results were seen after treatment with
temsirolimus, including a decrease in cell numbers by 48
hours to below the levels at the hour zero time-point (Figure
2B). When the serum–starved IMR–32 cells were incubated
with rapamycin or temsirolimus for 24 or 48 hours similar
results were obtained with the exception of the treatment
group that received the lowest drug concentration (Figure 3).
The groups, which received 1 ng/ml of rapamycin or 1 ng/ml
of temsirolimus, did not show a significant difference in cell
number after 24 hours of incubation, although cytotoxicity
was demonstrable at 48 hours.
Effect of inhibition of IGF1R alone or in combination with
mTOR blockade. When serum-starved cells were incubated
with 0.5 μg/ml of αIR3, alone or in combination with 1 ng/ml
rapamycin for 24 or 48 hours, the cell number did not
increase compared to the untreated control cultures (Figure
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Figure 1. IGF system expression in BE-2(c) and IMR-32 cell lines, analyzed by RT-PCR of RNA extracted from the cells. Neither IGF-1 or IGFBP-
1 were amplified. The other IGF system genes studied were amplified and were of the predicted sizes in both cell lines: IGF-II, 419 bp; IGF1R, 545
bp; IGFBP-2, 271 bp; IGFBP-3, 287 bp; IGFBP-4, 179 bp; IGFBP-5, 332 bp; IGFBP-6, 397 bp. Note the presence of an increased amount of IGF-
II RNA in the BE–2 (c) cell line. Replicons were subjected to sequencing (University of North Carolina Automated Sequencing Facility) to confirm
their identity. 18 S: ribosomal RNA, positive control.
4A and Figure 5A). Similar results were found after
incubation with 10 ng/ml temsirolimus, alone or in
combination with 0.5 μg/ml of αIR3 (Figures 4B and 5B),
with the exception of the 0.5 μg/ml αIR3 treatment group in
the BE–2(c) cell culture (Figure 4B). This treatment group
did not show a statistically significant difference in the cell
number when compared to the control.
A combination of both agents showed a statistically
significant reduction in cell number when compared to
untreated controls in both cell types (Figures 4 and 5).
Furthermore, following the combination treatment, the total
cell number in the BE-2(c) and IMR–32 cultures at 24 and
48 hours declined to levels below those at the zero time-
point, indicating that cell survival deteriorated.
Blockade of mTOR in combination with IGF1R inhibition
and propidium iodide fluorescence. mTOR blockade, alone
or in combination with IGF1R inhibition with αIR3
increased PI fluorescent cells (dying cells) in the BE–2(c)
and IMR–32 cell cultures (Figure 6). The combination of
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Figure 2. Dose response of BE–2(c) cells to rapamycin and
temsirolimus. Cell number in control and treated cells plated at 104 cells
per well. Time zero represents serum starved untreated cells from each
experimental group prior to treatment. A) Absolute cell counts are
shown after 24 and 48 hours in control medium (CM) (CTL) or CM
plus 1, 10 or 100 ng/ml rapamycin. *p<0.05 compared to CM (CTL). B)
Absolute cell counts are shown 24 and 48 hours after treatment with
CM (CTL), CM (CTL) or CM plus 1, 10, or 100 ng/ml temsirolimus.
*p<0.05 compared to CM (CTL).
Figure 3. Dose response of IMR-32 cells to rapamycin and temsirolimus.
Cell number in control and treated cells plated at 104 cells per well.
Time zero represents serum starved untreated cells from each
experimental group prior to treatment. A) Absolute cell counts are
shown 24 and 48 hours after treatment with CM (CTL) or CM plus 1,
10 or 100 ng/ml rapamycin. *p<0.05 compared to CM (CTL). B)
Absolute cell counts are shown 24 and 48 hours after treatment with
CM (CTL) or CM plus 1, 10 or 100 ng/ml temsirolimus. *p<0.05
compared to CM (CTL).
αIR3 with rapamycin or temsirolimus appeared to induce
greater cell death than αIR3, rapamycin, or temsirolimus
alone.
Discussion
The BE–2(c) and IMR-32 neuroblastoma-derived cell lines
synthesized a number of IGF system components including
IGF-II, IGF1R and IGFBPs 2-6. These results were expected
and agree with previously published data for other
neuroblastoma-derived cell lines (21). IGF-II has been
indicated as both an autocrine and paracrine growth factor
for neuroblastoma, and has also been found to induce the
production of MYC-N (21). Because the MYC-N gene copy
number is 5-fold greater in BE–2(c) cells than in IMR-32
cells, the more abundant expression of IGF-II in the BE-2(c)
Coulter et al: IGF-I and mTOR Inhibition in Neuroblastoma
1513
Figure 4. Combination of rapamycin or temsirolimus and αIR3
treatment of BE–2(c) cells. Cells were plated at 104 cells per well. Time
zero represents serum starved untreated cells from each experimental
group prior to treatment. A) Absolute cell counts are shown 24 and 48
hours after treatment with CM (CTL), CM plus 0.5 μg/ml IgG (IgG),
CM plus 0.5 μg/ml αIR3 (αIR3), CM plus 1 ng/ml rapamycin (RAP),
CM plus 1ng/ml rapamycin plus 0.5 μg/ml αIR3 (COMBO). *p<0.05
compared to CM (CTL). B) Absolute cell counts are shown 24 and 48
hours after treatment with CM (CTL), CM plus 0.5 μg/ml IgG (IgG),
CM plus 0.5 μg/ml αIR3 (αIR3), CM plus 10 ng/ml temsirolimus
(TEM), CM plus 10 ng/ml temsirolimus plus 0.5 μg/ml αIR3 (COMBO).
*p<0.05 compared to CM (CTL).
Figure 5. Treatment of IMR-32 cells with rapamycin or temsirolimus
and αIR3. Cells were plated at 105 cells per well. Time zero represents
serum starved untreated cells from each experimental group prior to
treatment. A) Absolute cell counts are shown 24 and 48 hours after
treatment with CM (CTL), CM plus 0.5 μg/ml IgG (IgG), CM plus 0.5
μg/ml αIR3 (αIR3), CM plus 1 ng/ml rapamycin (RAP) or CM plus 1
ng/ml rapamycin plus 0.5 μg/ml αIR3 (COMBO). *p<0.05 compared to
CM (CTL). B) Absolute cell counts are shown 24 and 48 hours after
treatment with CM (CTL), CM plus 0.5 μg/ml IgG (IgG), CM plus
0.5μg/ml αIR3 (αIR3), CM plus 10 ng/ml temsirolimus (TEM) or CM
plus 10 ng/ml temsirolimus plus 0.5 μg/ml αIR3 (COMBO). *p<0.05
compared CM (CTL).
cells was consistent with the evidence that IGF-II induces
MYC-N (21).
The mTOR blockade treatment of the BE–2(c) cells with
rapamycin or temsirolimus decreased the overall cell number
in a dose dependent manner. Similar results were seen for
the IMR–32 cell line, with the exception of the lowest
concentration of either rapamycin or temsirolimus (1 ng/ml)
at 24 hours. The failure of the lower concentrations to inhibit
cell growth at 24 hours may have been due to the slower
growth rate of the IMR–32 cells (24 hours) when compared
to the BE–2(c) cells (18 hours), and therefore a delay in
metabolizing the drug. This possibility was supported by data
showing a statistically significant decrease of cell number in
the IMR–32 line 48 hours after incubation with 1 ng/ml of
either rapamycin or temsirolimus.
The monoclonal antibody αIR3 which acts as an IGF1R
antagonist (22) also abrogated the increase in cell number
stimulated by serum addition to serum starved cells at 48
ANTICANCER RESEARCH 28: 1509-1516 (2008)
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Figure 6. Propidium Iodide staining of treated BE–2(c) and IMR–32 cells. A) BE–2(c) cells and B) IMR-32 cells grown in media containing
propidium iodide and treated with CM (CTL), CM plus 0.5 μg/ml IgG (IgG), CM plus 0.5 μg/ml αIR3 (αIR3), CM plus 1 ng/ml rapamycin (RAP),
CM plus 10 ng/ml temsirolimus (TEM), CM plus 1 ng/ml rapamycin plus 0.5 μg/ml αIR3 (RAP + αIR3), and CM plus 10 ng/ml temsirolimus plus
0.5 μg/ml αIR3 (TEM + αIR3). *p<0.05 compared to control.
hours, consistent with blockage of IGF1R signaling
effectively blocking proliferation. The αIR3 antibody has
been shown to decrease proliferation in vitro in a broad range
of tumor cell lines, including neuroblastoma (4). The
significant decreases in cell numbers which resulted from
treatment with αIR3 in the present study also were in line
with prior studies of IGF-I pro-survival action (4). These data
were consistent with arrest at the G1/S-phase checkpoint of
the cell cycle resulting from an absence of IGF1R signaling.
When αIR3 and rapamycin or temsirolimus were used in
combination, the decline in cell number was greater than when
each agent was used alone. Furthermore, the cell number
decreased to levels below the zero time-point. Although cell
growth was not as robust in the temsirolimus treated BE-2(c)
cells (Figure 4B), the control groups, CTL and IgG, doubled
in number by 48 hours while the number of cells in the
combination treated group (COMBO) decreased significantly
below the level of the serum starved group. The reduction in
cell number was greater than could be accounted for by cell
cycle arrest, and suggested the occurrence of cell death. Clear
evidence of increased numbers of dying cells in cultures
treated with rapamycin, temsirolimus, or a combination of
either agent with αIR3 was shown by propidium iodide
staining (Figure 6). The combination of αIR3 and rapamycin
or temsirolimus was more effective in inducing cell death at
24 hours than rapamycin or temsirolimus alone. This finding
was consistent with both agents acting through the same
pathway. The data were also in agreement with other studies
which have shown that combined mTOR and IGF1R
inhibition in rhabdomyosarcoma cell lines resulted in additive
cytotoxicity (23).
In conclusion, neuroblastoma cells express multiple
components of the IGF system, and a combination of
rapamycin or temsirolimus with αIR3 is able to block the
IGF1R signaling pathway more effectively and has more
anti-proliferative effect than either agent alone. The present
study represents the first use of temsirolimus in pediatric
tumors in the medical literature. Studies evaluating the
mechanism of cell death induced by these agents, and the
possible impact of IGF1R blockade on MYC-N protein
expression are currently underway. It will be necessary to
understand the regulation of IGF1R signaling and the
complex interplay of the IGF1R and mTOR signaling
pathways before their role in neuroblastoma growth can be
elucidated, and hopefully the development of novel
therapeutics for neuroblastoma can be initiated.
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